دواعي استعمال تيربناسيل 250 مجم 14 قرص

Terbinasil 250 mg tablets: oral terbinafine 250 mg tablets (allylamine antifungal), pack of 14.

• Onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium); confirm diagnosis by nail specimen testing before treatmentالفئة: AdultsDailyMed (U.S. National Library of Medicine)

• Most frequent trial adverse events included gastrointestinal symptoms (diarrhea, dyspepsia, abdominal pain), liver test abnormalities, rashes, urticaria, pruritus and taste disturbance.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Chronic or active liver disease.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• History of allergic reaction to oral terbinafine (risk of anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Hepatotoxicity: liver failure, some leading to transplant or death, has occurred; perform liver function tests before prescribing.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Taste and smell disturbance, including loss, may be prolonged or permanent; discontinue if they occur.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Depressive symptoms have been reported; patients should report them.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Serious skin/hypersensitivity reactions (SJS, TEN, erythema multiforme, DRESS) reported; discontinue if progressive rash occurs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Precipitation or exacerbation of cutaneous and systemic lupus erythematosus reported; discontinue if suspected.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Thrombotic microangiopathy (TTP/HUS), some fatal, reported; discontinue if consistent findings occur.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• CYP2D6 substrates (tricyclic antidepressants, SSRIs, beta-blockers, class 1C antiarrhythmics, MAO-B inhibitors)Terbinafine inhibits CYP2D6; coadminister with careful monitoring and possible dose reduction of the 2D6-metabolized drug.DailyMed (U.S. National Library of Medicine)

• Postmarketing data are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage or adverse outcomes; animal studies showed no malformations.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Terbinafine is present in human milk after oral use; no data on effects on the breastfed child.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Liver function tests before initiating treatment.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Consider complete blood counts in patients with known or suspected immunodeficiency if treatment exceeds 6 weeks (transient lymphocyte decreases).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• تيربينافين: Inhibits fungal squalene epoxidase, blocking ergosterol biosynthesis; squalene accumulation causes fungal cell death (US label 12.4).مضاد فطريات من فئة الأليلامين